These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35460587)

  • 1. Survival of dogs with pituitary-dependent hyperadrenocorticism treated twice daily with low doses of trilostane.
    García San José P; Arenas Bermejo C; Alonso-Miguel D; González Sanz S; Clares Moral I; Portero Fuentes M; Pérez-Alenza MD
    Vet Rec; 2022 Aug; 191(3):e1630. PubMed ID: 35460587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
    Arenas C; Melián C; Pérez-Alenza MD
    J Vet Intern Med; 2013; 27(6):1478-85. PubMed ID: 24118316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.
    Nagata N; Kojima K; Yuki M
    J Vet Intern Med; 2017 Jan; 31(1):22-28. PubMed ID: 27906457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism.
    Alenza DP; Arenas C; Lopez ML; Melian C
    J Am Anim Hosp Assoc; 2006; 42(4):269-76. PubMed ID: 16822765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
    Cho KD; Kang JH; Chang D; Na KJ; Yang MP
    J Vet Intern Med; 2013; 27(1):91-8. PubMed ID: 23167780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
    Braddock JA; Church DB; Robertson ID; Watson AD
    Aust Vet J; 2003 Oct; 81(10):600-7. PubMed ID: 15080470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism.
    Barker EN; Campbell S; Tebb AJ; Neiger R; Herrtage ME; Reid SW; Ramsey IK
    J Vet Intern Med; 2005; 19(6):810-5. PubMed ID: 16355673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
    Feldman EC
    J Am Vet Med Assoc; 2011 Jun; 238(11):1441-51. PubMed ID: 21627507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
    Griebsch C; Lehnert C; Williams GJ; Failing K; Neiger R
    J Vet Intern Med; 2014; 28(1):160-5. PubMed ID: 24341822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of dogs with adrenal-dependent hyperadrenocorticism: a comparison between mitotane and twice daily trilostane treatment.
    Arenas C; Melián C; Pérez-Alenza MD
    J Vet Intern Med; 2014; 28(2):473-80. PubMed ID: 24495125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum adipokine concentrations in dogs with naturally occurring pituitary-dependent hyperadrenocorticism.
    Cho KD; Paek J; Kang JH; Chang D; Na KJ; Yang MP
    J Vet Intern Med; 2014; 28(2):429-36. PubMed ID: 24372863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of factors that influence survival in dogs with adrenal-dependent hyperadrenocorticism treated with mitotane or trilostane.
    Helm JR; McLauchlan G; Boden LA; Frowde PE; Collings AJ; Tebb AJ; Elwood CM; Herrtage ME; Parkin TD; Ramsey IK
    J Vet Intern Med; 2011; 25(2):251-60. PubMed ID: 21352377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism.
    Clemente M; De Andrés PJ; Arenas C; Melián C; Morales M; Pérez-Alenza MD
    Vet Rec; 2007 Dec; 161(24):805-9. PubMed ID: 18083978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in systolic blood pressure in dogs with pituitary dependent hyperadrenocorticism during the first year of trilostane treatment.
    García San José P; Arenas Bermejo C; Alonso-Miguel D; Clares Moral I; Cuesta-Alvaro P; Pérez Alenza MD
    J Vet Intern Med; 2021 Jan; 35(1):130-141. PubMed ID: 33274787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
    Boretti FS; Holzthüm J; Reusch CE; Sieber-Ruckstuhl NS
    Schweiz Arch Tierheilkd; 2016 Sep; 158(9):631-638. PubMed ID: 27655162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
    Ruckstuhl NS; Nett CS; Reusch CE
    Am J Vet Res; 2002 Apr; 63(4):506-12. PubMed ID: 11939311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
    Vaughan MA; Feldman EC; Hoar BR; Nelson RW
    J Am Vet Med Assoc; 2008 May; 232(9):1321-8. PubMed ID: 18447776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs.
    Bell R; Neiger R; McGrotty Y; Ramsey IK
    Vet Rec; 2006 Aug; 159(9):277-81. PubMed ID: 16946310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane.
    Fracassi F; Corradini S; Floriano D; Boari A; Aste G; Pietra M; Bergamini PF; Dondi F
    Vet Rec; 2015 Jan; 176(2):49. PubMed ID: 25170036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
    Sieber-Ruckstuhl NS; Boretti FS; Wenger M; Maser-Gluth C; Reusch CE
    Domest Anim Endocrinol; 2006 Jul; 31(1):63-75. PubMed ID: 16233969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.